Zhejiang H1N1 vaccine has passed the review. Zui will be available next week

On August 31, the influenza A (H1N1) vaccine produced by Beijing Kexing Biological Products Co., Ltd passed the review and was approved to be put into production for human vaccination The eggs of hens hatched from the 9th to 10th day (the eggs cooked at this time are the happy eggs) were injected into the virus strain to become the chicken embryo The virus was formally cultured and observed for 48-72 hours after injection On August 31st, the influenza A H1N1 vaccine produced by Beijing Kexing Biological Products Co., Ltd passed the review and was approved to be put into production for human vaccination The influenza A (H1N1) vaccine produced by Zhejiang Tianyuan bio Pharmaceutical Co., Ltd., located in Yuhang, Hangzhou, has also passed the expert review The Ministry of science and Technology launched the "joint prevention and control of influenza A and H1N1 emergency scientific research project" and established the strategic alliance of influenza vaccine technology innovation There are nine companies producing vaccines, including Beijing Science and Technology Development Co., Ltd and Zhejiang Tianyuan * batch preparation of 120000 ml vaccine for injection yesterday, Ms Huo Haiqin from the quality assurance department of Zhejiang Tianyuan bio Pharmaceutical Co., Ltd asked her to talk about the process of vaccine production - first to obtain the virus strain, which refers to the virus isolated from the human body, this strain is provided by the British Institute of biological products, a supplier designated by the World Health Organization The eggs of hens hatched for 9-10 days (the eggs cooked at this time are happy eggs) were injected into the virus strain to become chicken embryos The virus was formally cultured and observed for 48-72 hours after injection The production personnel illuminated the eggs with lights to observe the maturity and development of chicken embryos, and removed the eggs with cracks, cracked shells and dead chickens Select the chicken embryo in good condition and put it into the ice house of 2 ℃ - 8 ℃, store it for about 8 days, let the virus breed in the chicken embryo; then harvest the virus: open the chicken embryo, like eating a happy egg, extract the juice from the egg - this is the virus liquid The next step is to remove the impurities in the virus solution through centrifugation, chemical extraction and other methods The first steps of each vaccine production company are the same, and different processes are used in this step At this time, the virus solution is concentrated and diluted in the human body Ms Huo said that the 120000 ml injection vaccine produced by the company in batches is expected to be sent to the drug approval center of the State Food and Drug Administration for testing on Friday, and Zui is expected to be put on the market soon next week to start vaccination After elimination of losses, 120000 ml of vaccine can be used by about 190000 people The vaccine can make the human body resistant In November last year, Zhejiang Province launched measles vaccine intensive immunization in the whole province At that time, Chen Enfu, director of the Institute of immunology and prevention of the center for Disease Control and prevention of Zhejiang Province, explained the principle of the vaccine - the vaccine is a live attenuated vaccine, which is to reduce the virus to basically non-toxic, and then implant it into the human body, artificially infect the virus, so that the virus can grow and reproduce in the human body The vaccine virus can make the human body produce resistance to the virus "The concentration of influenza A (H1N1) vaccine should not be too high, or vaccination will lead to serious illness." Huo Haiqin said Zhejiang Tianyuan's influenza A (H1N1) vaccine has recruited hundreds of volunteers, all of whom are over 3 years old, each of whom is injected with 0.5ml vaccine After injection, there is no obvious adverse reaction, only slight reactions such as swelling and pain appear at the injection site The vaccine will be given priority to key groups of people Chen Zhu, Minister of health, said that influenza A (H1N1) vaccine has entered the vaccination stage, and * step will be vaccinated to vulnerable groups, such as people with basic diseases, workers in special fields, etc According to the Zhejiang Provincial Department of health, the order of vaccine use in Zhejiang Province will be based on the order of core population, high-risk population, key population and applicable population The core population refers to the relevant personnel dealing with the epidemic situation; the high-risk population includes the entry-exit reception personnel, epidemic prevention and control material production personnel, as well as the medical personnel in the fever clinic and the infection clinic; the key population includes the chronic patients and those with multiple diseases; the applicable population includes children, students and the elderly The World Health Organization will track the evolution of influenza, disclose information in a timely manner, define which people are at high risk of influenza, and let countries refer to the people who decide to give priority to vaccination